Chemistry, pharmacology, and clinical efficacy of the Chinese nootropic agent huperzine A

Accounts of Chemical Research

Volumn 32, Issue 8, 1999, Pages 641-650

  Kozikowski, Alan P ^a   Tückmantel, Werner ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHINESE DRUG; DRUG DERIVATIVE; EXCITATORY AMINO ACID; HUPERZINE A; QUINALDINE;

ALZHEIMER DISEASE; DRUG CONFORMATION; DRUG EFFICACY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR MODEL; REVIEW; X RAY ANALYSIS;

EID: 0345034775     PISSN: 00014842     EISSN: None     Source Type: Journal    
DOI: 10.1021/ar9800892     Document Type: Review

References (62)

1. Liu, J.-S.; Zhu, Y.-L.; Yu, C.-M.; Zhou, Y.-Z.; Han, Y.-Y.; Wu, F.-W.; Qi, B.-F. The Structures of Huperzine A and B, Two New Alkaloids Exhibiting Marked Anticholinesterase Activity. Can J. Chem. 1986, 64, 837-839.
2. Kozikowski, A. P.; Thiels, E.; Tang, X.-C.; Hanin, I. Huperzine A-A Possible Lead Structure in the Treatment of Alzheimer's Disease. In Advances in Medicinal Chemistry, Maryanoff, B. E., Maryanoff, C. A., Eds.; JAI Press: Greenwich, CT, 1992; Vol. 1, pp 175-205.
3. Duke, J. A.; Ayensu, E. S. Medicinal Plants of China; Reference Publications, Vol. 2.
4. Xu, S.-S.; Gao, Z.-X.; Weng, S.; Du, Z.-M.; Xu, W.-A.; Yang, J.-S.; Zhang, M.-L.; Tong, Z.-H.; Fang, Y.-S.; Chai, X.-S.; Li, S.-L. Efficacy of Tablet Huperzine-A on Memory, Cognition, and Behavior in Alzheimer's Disease. Acta Pharmacol. Sin. 1995, 16, 391-395.
5. Schultes, R. E. Plants in Treating Senile Dementia in the Northwest Amazon. J. Ethnopharmacol. 1993, 38, 129-135. Another novel physostigmine analogue, phenserine, is also being readied for clinical studies. See: Greig, N. H.; Pei, X. F.; Soncrant, T.; Ingram, D. K.; Brossi, A. Phenserine and Ring C Hetero-Analogues: Drug Candidates for Treatment of Alzheimer's Disease. Med. Res. Rev. 1995, 15, 3-31.
6. Schultes, R. E. Plants in Treating Senile Dementia in the Northwest Amazon. J. Ethnopharmacol. 1993, 38, 129-135. Another novel physostigmine analogue, phenserine, is also being readied for clinical studies. See: Greig, N. H.; Pei, X. F.; Soncrant, T.; Ingram, D. K.; Brossi, A. Phenserine and Ring C Hetero-Analogues: Drug Candidates for Treatment of Alzheimer's Disease. Med. Res. Rev. 1995, 15, 3-31.
7. Mucke, H. A. M. Principles of Therapeutics with Galanthamine. Drugs Today 1997, 33, 251-257. Parnetti, L.; Senin, U.; Mecocci, P. Cognitive Enhancement Therapy for Alzheimer's Disease. The Way Forward. Drugs 1997, 53, 752-768.
8. Mucke, H. A. M. Principles of Therapeutics with Galanthamine. Drugs Today 1997, 33, 251-257. Parnetti, L.; Senin, U.; Mecocci, P. Cognitive Enhancement Therapy for Alzheimer's Disease. The Way Forward. Drugs 1997, 53, 752-768.
9. Porsolt, R. D. The Silent Epidemic: the Search for Treatment of Age-Related Memory Impairment. Trends Pharmacol Sci. 1989, 10, 3-6.
10. Hoffman, C.; Rice, D.; Sung, H. Y. Persons with Chronic Conditions. Their Prevalence and Costs. J. Am. Med. Assoc. 1996, 276, 1473-1479.
11. Weinstock, M. The Pharmacotherapy of Alzheimer's Disease Based on the Cholinergic Hypothesis: an Update. Neurodegeneration 1995, 4, 349-356.
12. Ashani, Y.; Peggins, J. O. III; Doctor, B. P. Mechanism of Inhibition of Cholinesterases by Huperzine A. Biochem. Biophys. Res. Commun. 1992, 184, 719-726.
13. Tang, X.-C.; Kindel, G. H.; Kozikowski, A. P.; Hanin, I. Comparison of the Effects of Natural and Synthetic Huperzine A on Rat Brain Cholinergic Function in vitro and in vivo. J. Ethnopharmacol. 1994, 44, 147-155.
14. Lees, G. Contributory Mechanisms in the Causation of the Neurodegenerative Disorders. J. Neurosci. 1993, 54, 287-322.
15. Gilman, S. Alzheimer's Disease. Perspect. Biol. Med. 1996, 40, 230-245.
16. Cotman, C. W.; Su, J.-H. Mechanisms of Neuronal Death in Alzheimer's Disease. Brain Pathol. 1996, 6, 493-506.
17. Selkoe, D. J. Physiological Production of the beta-Amyloid Protein and the Mechanism of Alzheimer's Disease. Trends Neurosci. 1993, 16, 403-409.
18. Brion, J. P. The Neurobiology of Alzheimer's Disease. Acta Clin. Belg. 1996, 51-2, 80-90.
19. Selkoe, D. J. Alzheimer's Disease: Genotypes, Phenotypes, and Treatments. Science 1997, 275, 630-631.
20. Hardy, J. Molecular Genetics of Alzheimer's Disease. Acta Neurol. Scand. 1996, 165, 13-17.
21. Mattson, M. P.; Guo, Q.; Furukawa, K.; Pedersen, W. A. Presenilins, the Endoplasmic Reticulum, and Neuronal Apoptosis in Alzheimer's Disease. J. Neurochem. 1998, 70, 1-14.
22. Etcheberrigaray, R.; Alkon, D. L. Potassium Channels and Calcium Release. In Molecular Mechanisms of Dementia; Wasco, W., Tanzi, R. E., Eds.; Humana Press: Totowa, NJ, 1997; pp 239-252.
23. Bhagavan, S.; Ibarreta, D.; Ma, D.; Kozikowski, A. P.; Etcheberrigaray, R. Restoration of TEA-Induced Calcium Responses in Fibroblasts from Alzheimer's Disease Patients by a PKC Activator. Neurobiol. Dis. 1998, 177-187.
24. Blacker, D.; Wilcox, M. A.; Laird, N. M.; Rodes, L.; Horvath, S. M.; Go, R. C. P.; Perry, R.; Watson, B.; Bassett, S. S.; McInnis, M. G.; Albert, M. S.; Hyman, B. T.; Tanzi, R. E. Alpha-2 Macroglobulin is Genetically Associated with Alzheimer Disease. Nat. Genet. 1998, 19, 357-360.
25. Sano, M.; Ernesto, C.; Klauber, M. R.; Schafer, K.; Woodbury, P.; Thomas, R.; Grundman, M.; Growdon, J.; Thal, L. J. Rationale and Design of a Multicenter Study of Selegiline and alpha-Tocopherol in the Treatment of Alzheimer Disease Using Novel Clinical Outcomes Alzheimer's Disease Cooperative Study. Alzheimer Dis. Assoc. Disord. 1996, 10, 132-140.
26. Velazquez, P.; Cribbs, D. H.; Poulos, T. L.; Tenner, A. J. Aspartate Residue 7 in Amyloid beta-Protein is Critical for Classical Complement Pathway Activation: Implications for Alzheimer's Disease Pathogenesis. Nat. Med. (N.Y.) 1997, 3, 77-79.
27. McKinney, M.; Kozikowski, A. P. Pharmacological Studies of Himbacine and Huperzine A: Potential Use in Cholinergic Replacement Therapy. In Herbal Medicines for Neuropsychiatric Diseases; Kanba, S., Ed.; Brunner/Mazel: New York; Seiwa Shoten: Tokyo, 1997; pp 2-11.
28. Rogers S. L.; Yamanishi, Y.; Yamatsu, K. In Cholinergic Basis for Alzheimer's Disease; Becker, R., Giacobini, E., Eds.; Birkhäuser: Boston, 1991; pp 314-320.
29. Becker, R. E.; Colliver, J. A.; Markwell, S. J.; Moriearty, P. L.; Unni, L. K.; Vicari, S. Effects of Metrifonate on Cognitive Decline in Alzheimer Disease: a Double-Blind, Placebo-Controlled, 6-Month Study. Alzheimer Dis. Assoc. Disord. 1998, 12, 54-57.
30. Weinstock, M.; Razin, M.; Chorev, M.; Enz, A. J. Pharmacological Evaluation of Phenyl-carbamates as CNS-Selective Acetylcholinesterase Inhibitors. Neural Transm. Suppl. 1994, 43, 219-225.
31. Ved, H. S.; Koeining, M. L.; Dave, J. R.; Doctor, B. P. Huperzine A, a Potential Therapeutic Agent for Dementia, Reduces Neuronal Cell Death Caused by Glutamate. Neuroreport 1997, 8, 963-968.
32. Etcheberrigaray, R. Personal communication. Also, see: Ibarreta, D.; Duchén, M.; Ma, D.; Qiao, L.; Kozikowski, A. P.; Etcheberrigaray, R. Benzolactam (BL) Enhances sAPP Secretion in Fibroblasts and in PC12 Cells. Neuroreport, in press.
33. Lallement, G.; Veyret, J.; Masqueliez, C.; Aubriot, S.; Burckhart, M. F.; Baubichon, D. Efficacy of Huperzine in Preventing Soman-Induced Seizures, Neuropathological Changes and Lethality. Fundam. Clin. Pharmacol. 1997, 11, 387-394.
34. Ashani, Y.; Grunwald, J.; Alkalai, D.; Cohen, G.; Raveh, L. Studies with Huperzine A, a New Candidate in the Research of Prophylaxis Against Nerve Agents. In 1996 Medical Defense Bioscience Review, Proceedings; King, J. M., Ed.; U.S. Army Medical Research and Material Command: Edgewood, MD, Vol. 1, pp 105-110.
35. Xia, Y.; Kozikowski, A. P. A Practical Synthesis of the Chinese Nootropic Agent Huperzine A: A Possible Lead in the Treatment of Alzheimer's Disease. J. Am. Chem. Soc. 1989, 111, 4116-4117.
36. Kozikowski, A. P.; Xia, Y.; Reddy, E. R.; Tückmantel, W.; Hanin, I.; Tang, X. C. Synthesis of Huperzine A and Its Analogues and their Anticholinesterase Activity. J. Org. Chem. 1991, 56, 4636-4645.
37. (a) Qian, L.; Ji, R. A Total Synthesis of (+-)-Huperzine A. Tetrahedron Lett. 1989, 30, 2089-2090.
38. (b) Ji, R. Studies on Molecular Modification of Novel Constituents of Chinese Medicinal Plants. Med. Chem. Res. 1995, 5, 587-594.
39. Colvin, E. W.; Martin, J.; Parker, W.; Raphael, R. A.; Shroot, B.; Doyle, M. Bridged Ring Systems. Part XVI. A Synthetic Approach to Lycopodium Alkaloids. J. Chem. Soc., Perkin Trans, 1 1972, 860-870.
40. Stork, G. Polycyclic Natural Products: Total Synthesis of Lycopodine. Pure Appl. Chem. 1968, 17, 383-401.
41. Kozikowski, A. P.; Reddy, E. R.; Miller, C. P. A Simplified Route to a Key Intermediate in the Synthesis of the Chinese Nootropic Agent Huperzine A. J. Chem. Soc., Perkin Trans. 1 1990, 195-197.
42. (a) Huang, Y.; Lu, X. Palladium Catalyzed Annulation Reaction Using A Bifunctional Allylic Alkylating Agent. Tetrahedron Lett. 1988, 29, 5663-5664.
43. (b) Gravel, D.; Benoît, S.; Kumanovic, S.; Sivaramakrishnan, H. On the Palladium Catalyzed Reaction of Methallyl-1,1-diacetate with Cyclic β-Ketoesters. Intervention of Hidden Mechanisms. Tetrahedron Lett. 1992, 33, 1407-1410.
44. (a) Kozikowski, A. P.; Campiani, G.; Aagaard, P.; McKinney, M. An Improved Synthetic Route to Huperzine A; New Analogues and Their Inhibition of Acetylcholinesterase. J. Chem. Soc., Chem. Commun. 1993, 860-862.
45. (b) Campiani, G.; Sun, L.-Q.; Kozikowski, A. P.; Aagaard, P.; McKinney, M. A Palladium-Catalyzed Route to Huperzine A and Its Analogues and Their Anticholinesterase Activity. J. Org. Chem. 1993, 58, 7660-7669.
46. Yamada, F.; Kozikowski, A. P.; Reddy, E. R.; Pang, Y.-P.; Miller, J. H.; McKinney, M. A Route to Optically Pure (-)-Huperzine A: Molecular Modeling and in Vitro Pharmacology. J. Am. Chem. Soc. 1991, 113, 4695-4696.
47. Kaneko, S.; Yoshino, T.; Katoh, T.; Terashima, S. Synthetic Studies of Huperzine A and Its Fluorinated Analogues. 1. Novel Asymmetric Syntheses of an Enantiomeric Pair of Huperzine A. Tetrahedron 1998, 54, 5471-5484 and references cited therein.
48. Kozikowski, A. P.; Miller, C. P.; Yamada, F.; Pang, Y.-P.; Miller, J. H.; McKinney, M.; Ball, R. G. Delineating the Pharmacophoric Elements of Huperzine A: Importance of the Unsaturated Three-Carbon Bridge to Its AChE Inhibitory Activity. J. Med. Chem. 1991, 34, 3399-3402.
49. Kozikowski, A. P.; Yamada, F. Unpublished results.
50. Xia, Y.; Reddy, E. R.; Kozikowski, A. P. Synthesis of the Benzenoid Analogue of the Chinese Nootropic Agent Huperzine A. Tetrahedron Lett. 1989, 30, 3291-3294.
51. Kozikowski, A. P.; Campiani, G.; Saxena, A.; Doctor, B. P. Unpublished results.
52. Kozikowski, A. P.; Campiani, G.; Tückmantel, W. An Approach to Open Chain and Modified Heterocyclic Analogues of the Acetylcholinesterase Inhibitor, Huperzine A, Through a Bicyclo[3.3.1]nonane Intermediate. Heterocycles 1994, 39, 101-116.
53. Kozikowski, A. P.; Tückmantel, W.; Saxena, A.; Doctor, B. P. Synthesis of the Thiazolone Analogue of the Acetylcholinesterase Inhibitor, Huperzine A. Helv. Chim. Acta 1994, 77, 1256-1265.
54. Kozikowski, A. P.; Campiani, G.; Nacci, V.; Sega, S.; Saxena, A.; Doctor, B. P. An Approach to Modified Heterocyclic Analogues of Huperzine A and Isohuperzine A. Synthesis of the Pyrimidone and Pyrazole Analogues, and Their Anticholinesterase Activity. J. Chem. Soc., Perkin Trans. I 1996, 1287-1297.
55. Danheiser, R. L.; Nowick, J. S. A Practical and Efficient Method for the Synthesis of β-Lactones. J. Org. Chem. 1991, 56, 1176-1185.
56. Li, Y. L.; He, X. C.; Bai, D. L. Synthesis of Analogues of Huperzine A. 4. The Preparation of a Pyrimidone Analogue of Huperzine A. Chin. Chem. Lett. 1996, 7, 111-114.
57. Kozikowski, A. P.; Campiani, G.; Sun, L.-Q.; Wang, S.; Saxena, A.; Doctor, B. P. Identification of a More Potent Analogue of the Naturally Occurring Alkaloid Huperzine A. Predictive Molecular Modeling of Its Interaction with AChE. J. Am. Chem. Soc. 1996, 118, 11357-11362.
58. Kozikowski, A. P.; Ding, Q.; Saxena, A.; Doctor, B. P. Synthesis of (±)-10,10-Dimethylhuperzine A-A Huperzine Analogue Possessing a Slower Enzyme Off-Rate. Bioorg. Med. Chem. Lett. 1996, 6, 259-262.
59. Kozikowski, A. P.; Prakash, K. R. C.; Saxena, A.; Doctor, B. P. Synthesis and Biological Activity of an Optically Pure 10-Spirocyclopropyl Analog of Huperzine A. J. Chem. Soc., Chem. Commun. 1998, 1287-1288.
60. Pang, Y.-P.; Kozikowski, A. P. Prediction of the Binding Sites of Huperzine A in Acetylcholinesterase by Docking Studies. J. Comput.-Aided Mol. Des. 1994, 8, 669-681.
61. Harel, H.; Schalk, I.; Ehret-Sabatier, L.; Bouet, F.; Goeldner, M.; Hirth, C.; Axelsen, P. H.; Silman, I.; Sussman, J. L. Quaternary Ligand Binding to Aromatic Residues in the Active-Site Gorge of Acetylcholinesterase. Proc. Natl Acad. Sci. U.S.A. 1993, 90, 9031-9035.
62. Raves, M.; Harel, M.; Pang, Y. P.; Silman, I.; Kozikowski, A. P.; Sussman, J. L. Structure of Acetylcholinesterase Complexed with the Nootropic Alkaloid, (-)-Huperzine A. Nat. Struct. Biol. 1997, 4, 57-63.